ARS-1 2mg for Urticaria

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Bernstein Clinical Research Center, LLC, Cincinnati, OH
Urticaria
ARS-1 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Determine the effect of ARS-1 on a patient reported pruritus/hive score

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Urticaria

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Assessment will start from 1 hour pre-dose to 120 (± 10 min) minutes after dosing.

Hour 1
Effect of ARS-1 versus placebo based on a patient reported pruritus/hive score

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Urticaria

Trial Design

3 Treatment Groups

ARS-1 2mg
1 of 3
ARS-1 1mg
1 of 3
Placebo
1 of 3
Active Control
Non-Treatment Group

32 Total Participants · 3 Treatment Groups

Primary Treatment: ARS-1 2mg · Has Placebo Group · Phase 2

ARS-1 2mg
Drug
ActiveComparator Group · 1 Intervention: ARS-1 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
ARS-1 1mg
Drug
ActiveComparator Group · 1 Intervention: ARS-1 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: assessment will start from 1 hour pre-dose to 120 (± 10 min) minutes after dosing.
Closest Location: Bernstein Clinical Research Center, LLC · Cincinnati, OH
Photo of Cincinnati  1Photo of Cincinnati  2Photo of Cincinnati  3
2003First Recorded Clinical Trial
2 TrialsResearching Urticaria
12 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a male or female between the ages of 18 and 65 years.
You are able to communicate clearly with the Investigator and staff.
You have urticaria with acute symptom flares at least two (2) times a week while on a chronic treatment.
You are male and agree to use highly effective contraceptive methods at screening until 7 days after the last day of study drug.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.